Filgotinib联合甲氨蝶呤或单药对比甲氨蝶呤单药治疗活动性类风湿关节炎:III期FINCH 3试验
这项52周III期随机双盲试验纳入1252例活动性RA且甲氨蝶呤(MTX)暴露有限或无暴露的患者,比较Filgotinib联合MTX或单药与MTX单药。第24周,FIL200+MTX组ACR20应答率81%显著高于MTX组71%(p<0.001),FIL100+MTX组80%(p=0.017);FIL200单药78%对比MTX 71%未达统计学优效(p=0.058)。
要点
- FIL200+MTX和FIL100+MTX均显著改善ACR20应答及身体功能,优于MTX单药。
- FIL200单药ACR20应答率未显著优于MTX单药(p=0.058)。
- 至52周不良事件发生率各治疗组相当,Filgotinib耐受性可接受。
核心结论
- FIL200+MTX和FIL100+MTX均显著改善活动性RA且MTX暴露有限或无暴露患者的症状体征和身体功能。
- FIL200单药对比MTX单药未显示ACR20应答率优效。
- Filgotinib耐受性良好,与MTX相比安全性可接受。
研究设计与样本
- 52周、III期、多中心、双盲临床试验(NCT02886728),纳入1252例RA患者。
- 患者按2:1:1:2随机分配至FIL200+MTX、FIL100+MTX、FIL200单药或MTX组,每日口服一次。
- 主要终点为第24周达到ACR20应答的患者比例。
主要发现
- 第24周,FIL200+MTX组81%患者达到ACR20,MTX组为71%(p<0.001)。
- 第24周,FIL100+MTX组80%患者达到ACR20,对比MTX组p=0.017。
- 第24周HAQ-DI最小二乘均值变化:FIL200+MTX组-1.0、FIL100+MTX组-0.94,MTX组-0.81(p<0.001、p=0.008)。
- 第24周DAS28(CRP)<2.6比例:FIL200+MTX组54%、FIL100+MTX组43%,MTX组29%(两组p均<0.001)。
- 第24周ACR20:FIL200单药组78%对比MTX组71%(p=0.058),层次检验终止。
关键数值与推荐
- 主要终点ACR20应答率:FIL200+MTX 81%、FIL100+MTX 80%、FIL200单药78%、MTX 71%。
- DAS28(CRP)<2.6比例:FIL200+MTX 54%、FIL100+MTX 43%、MTX 29%。
- HAQ-DI最小二乘均值变化:FIL200+MTX -1.0、FIL100+MTX -0.94、MTX -0.81。
临床怎么用
- 对于活动性RA且MTX暴露有限或无暴露的患者,可考虑Filgotinib 200mg或100mg联合MTX治疗以改善ACR20应答和身体功能。
- Filgotinib 200mg单药未显示优于MTX单药的ACR20应答率,选择单药方案需权衡。
- 至52周不良事件发生率与MTX相当,支持Filgotinib联合MTX的安全性可接受。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate efficacy and safety of the Janus kinase-1 inhibitor filgotinib in patients with active rheumatoid arthritis (RA) with limited or no prior methotrexate (MTX) exposure. METHODS: This 52-week, phase 3, multicentre, double-blind clinical trial (NCT02886728) evaluated once-daily oral filgotinib in 1252 patients with RA randomised 2:1:1:2 to filgotinib 200 mg with MTX (FIL200 +MTX), filgotinib 100 mg with MTX (FIL100 +MTX), filgotinib 200 mg monotherapy (FIL200), or MTX. The primary endpoint was proportion achieving 20% improvement in American College of Rheumatology criteria (ACR20) at week 24. RESULTS: The primary endpoint was achieved by 81% of patients receiving FIL200+ MTX versus 71% receiving MTX (p<0.001). A significantly greater proportion treated with FIL100+ MTX compared with MTX achieved an ACR20 response (80%, p=0.017) at week 24. Significant improvement in Health Assessment Questionnaire-Disability Index was seen at week 24; least-squares mean change from baseline was -1.0 and -0.94 with FIL200+MTX and FIL100+MTX, respectively, versus -0.81 with MTX (p<0.001, p=0.008, respectively). Significantly higher proportions receiving FIL200+MTX (54%) and FIL100+MTX (43%) achieved DAS28(CRP) <2.6 versus MTX (29%) (p<0.001 for both) at week 24. Hierarchical testing stopped for comparison of ACR20 for FIL200 monotherapy (78%) versus MTX (71%) at week 24 (p=0.058). Adverse event rates through week 52 were comparable between all treatments. CONCLUSIONS: FIL200+MTX and FIL100+MTX both significantly improved signs and symptoms and physical function in patients with active RA and limited or no prior MTX exposure; FIL200 monotherapy did not have a superior ACR20 response rate versus MTX. Filgotinib was well tolerated, with acceptable safety compared with MTX.
引用
- Westhovens R, Rigby WFC, van der Heijde D, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021. PMID: 33452004. doi:10.1136/annrheumdis-2020-219213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。